NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
NHS England · £2,028,332,000 · closes 7 Apr 2025
£2,028,332,000
Estimated value
Closed
Deadline
17 Feb 2025
Published
This tender has closed.
See what's open in medical equipment and pharmaceuticals, or get contracts like this in your inbox each morning — free.
About this contract
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk
Key dates
Source
Who to contact
Tender documents
Similar open tenders
Contains public sector information licensed under OGL v3.0